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Most lethal solid tumors including hepatocellular carcinoma (HCC) are considered
incurable due to extensive heterogeneity in clinical presentation and tumor biology.
Tumor heterogeneity may result from different cells of origin, patient ethnicity, etiology,
underlying disease, and diversity of genomic and epigenomic changes which drive tumor
development. Cancer genomic heterogeneity thereby impedes treatment options and
poses a significant challenge to cancer management. Studies of the HCC genome have
revealed that although various genomic signatures identified in different HCC subgroups
share a common prognosis, each carries unique molecular changes which are linked to
different sets of cancer hallmarks whose misregulation has been proposed by Hanahan
and Weinberg to be essential for tumorigenesis. We hypothesize that these specific sets
of cancer hallmarks collectively occupy different tumor biological space representing the
misregulation of different biological processes. In principle, a combination of different
cancer hallmarks can result in new convergent molecular networks that are unique to each
tumor subgroup and represent ideal druggable targets. Due to the ability of the tumor to
adapt to external factors such as treatment or changes in the tumor microenvironment, the
tumor biological space is elastic. Our ability to identify distinct groups of cancer patients
with similar tumor biology who are most likely to respond to a specific therapy would
have a significant impact on improving patient outcome. It is currently a challenge to
identify a particular hallmark or a newly emerged convergent molecular network for a
particular tumor. Thus, it is anticipated that the integration of multiple levels of data such as
genomic mutations, somatic copy number aberration, gene expression, proteomics, and
metabolomics, may help us grasp the tumor biological space occupied by each individual,
leading to improved therapeutic intervention and outcome.
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Like other lethal solid tumors, most primary liver cancer patients
are considered incurable due to extensive heterogeneity in clinical
presentation and tumor biology. Thereby, tumor heterogeneity
may result from different cells of origin, the range in patient
ethnicity, etiology, underlying disease and diversity of genomic
and epigenomic changes, which drive tumor development (Shen
and Laird, 2013). Molecular differences between tumors from
different patients, inter-tumor heterogeneity, and between dif-
ferent areas of an individual tumor, intra-tumor heterogeneity,
have been recognized, possibly emanating from the presence of
cancer stem cells or selection by clonal evolution (Nguyen et al.,
2012). Cancer genomic heterogeneity thereby results in vary-
ing degrees of clinical presentation and tumor biology, which
impedes treatment options and poses a significant challenge to
cancer management. Despite great progress in the development
of new treatment modalities, the improvement of cancer mortal-
ity is very modest, especially for common lethal cancers such as
esophageal, liver, lung, and pancreatic cancer (American Cancer
Society, 2012). Molecularly targeted therapies are promising new
treatment options, however, they may not fundamentally reduce
overall mortality in an unstratified cohort. For example, the first-
line treatment for advanced hepatocellular carcinoma (HCC),
sorafenib, a small molecular inhibitor of several tyrosine pro-
tein kinases, provides only a 2.8 month improvement of overall
median survival (Llovet et al., 2008). On the other hand, selec-
tion of patients that may respond to a specific treatment may
lead to greatly improved outcome. For example, the tyrosine
kinase inhibitor gefitinib has been shown to be effective in a
select group of non-small cell lung cancer patients with epider-
mal growth factor receptor (EGFR) mutations, providing a 13.5
month improvement of median overall survival (Takano et al.,
2005). Interferon-alpha is effective in preventing tumor relapse in
a select group of HCC patients with reduced expression of miR-26
in tumor cells, with an estimated improvement of median overall
survival of more than 7-years (Ji et al., 2009). Therefore, themajor
hurdle in fundamentally improving cancer patient outcome is
tumor heterogeneity. This is evident by the fact that current treat-
ment modalities appear to only be effective in a small group of
patients with select biological alterations underlying the consid-
erable influence of inter and intra-tumor heterogeneity on clinical
advances. Thus, our ability to identify distinct groups of can-
cer patients with similar tumor biology who are most likely to
respond to a specific therapy would have a significant impact on
improving patient outcome.
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To address this problem, molecular-based technologies includ-
ing genomic, transcriptomic, proteomic, and metabolomic
profiling, have been applied to clinical specimens of multiple can-
cer types with the aim of identifying distinct tumor subgroups
with unique tumor biology, which house critical and specific
alterations in gatekeepers of cancer initiation and progression.
Consequently, various genome-based signatures have been devel-
oped as diagnostic or prognostic tools to discriminate patients
with inter-tumor heterogeneity, assist in molecular re-staging or
predict outcome. These studies, which include matched case con-
trol specimens, homogenous patient populations of the same
etiology and independent cohorts for validation, have aided in the
successful identification of specific genomic aberrations necessary
for tumor growth and maintenance. Examples include signatures
linked to metastasis, tumor recurrence, inactivation of specific
tumor suppressor genes such as TP53 and cancer stem cells (Lee
et al., 2004; Budhu et al., 2006; Yamashita et al., 2009; Woo et al.,
2011). In addition, molecularly-guided technologies might com-
plement diagnostic classification, allowing physicians to predict
patient outcome and to select the most appropriate treatment for
each cancer patient. These approaches would allow us to triage
patients into homogeneous groups, each of which is linked to spe-
cific genomic aberrations with biological implications, whichmay
respond to a particular treatment (Roessler et al., 2007; Kumar
et al., 2011).
Over the last 10 years, multiple prognostic gene signatures
within the same cancer type have emerged from omics studies,
which raise questions about their biological significance. Are cer-
tain gene signatures identifying particular patient subgroups with
the same or different molecular traits? We examined this prob-
lem in the context of HCC as we and others have developed
multiple prognostic gene signatures within the same cohort of
HCC patients, which have been validated in independent patient
cohorts (Table 1 and Supplemental Information). To this end,
we compared 7 different gene signatures that are individually
associated with survival in the same HCC cohort. The first gene
signature we assessed consists of 153 genes associated with por-
tal venous metastases (Ye et al., 2003). This signature not only
predicts metastasis at the time of diagnosis, but also recurrence
within 2 years after diagnosis in early stage patients (Roessler
et al., 2010). A second gene signature, a driver gene signature,
was recently developed by integrating transcriptomic and somatic
copy number aberration profiling and consists of 10 genes that
show correlation between gene expression and chromosomal
alteration (Roessler et al., 2012). The third signature is a 65-gene
based risk score classifier built by the overlap of a proliferation
and a recurrence signature (Kim et al., 2012). A fourth signature
composed of 770 genes was developed by comparison of patients
associated with miR-26 expression (Ji et al., 2009), while the fifth
signature was related to fatty acid metabolism (FAM; n = 273)
(Budhu et al., 2013). Two additional unpublished gene signatures
were included, an unsupervised survival signature not restricted
to any phenotype (Cox proportional hazards model; n = 336;
p < 0.001) and a hepatic stem cell-like signature (n = 932; Zhao
et al., unpublished). A comparison of these 7 signatures shows
that they are mainly associated with different altered pathways
and cellular functions. From this result, we would expect that the
signatures predict different patient subgroups linked to pertur-
bations of their corresponding pathways. To test this hypothesis,
we performed subgroup prediction using the 7 gene signatures
followed by hierarchical clustering of the prediction results. We
found that patients largely separated into two clusters with con-
cordant survival prediction (Figure 1A). The driver signature
tends to assign high risk of poor outcome to more patients when
compared to the other signatures. Thus, a group of patients has
high risk only according to this signature. It appears that the
gene signatures are superior to TP53 mutation, tumor size and
clinical staging. As expected, the genes of the above 7 gene signa-
tures did not show significant overlap (hypergeometric test; alpha
< 0.05; Figure 1B). Thus, despite variances in gene alteration
among these signatures, they seem to differentiate concordant
patient outcome groups.
The high heterogeneity observed in the HCC population
would have suggested that multiple patient subgroups exist,
each of which share similar tumor biology. Ten cancer hall-
marks have been suggested to be required for tumorigenesis:
sustaining proliferative signaling, evading growth suppressors,
resisting cell death, enabling replicative immortality, inducing
angiogenesis, activating invasion, avoiding immune destruction,
tumor-promoting inflammation, deregulating cellular energetics
and genome instability and mutation (Hanahan and Weinberg,
2011). Thereby, each tumor exhibits a subset of cancer hall-
marks at differing degrees, which hypothetically might be ideal
therapeutic targets. However, if each gene signature predicts the
same poor outcome group, what is the main cancer hallmark
that is affected and what is the ideal treatment for this patient
subgroup? Joan Massagué introduced the concept of prognos-
tic space, which refers to the range of prognostic possibilities
specified by a particular prognostic indicator (Massague, 2007).
Thereby, distinct gene signatures that do not show any overlap
Table 1 | Seven outcome-related HCC gene signatures.
Classifier Main function Genes Key genes References
FAM Fatty acid metabolism 273 SCD Budhu et al., 2006, 2013
Metastasis Early recurrence 160 OPN Ye et al., 2003; Roessler et al., 2012
Driver genes Survival 10 8p genes, DLC1 etc. Roessler et al., 2012
Proliferation Proliferation 65 CTNNB1, AKT Kim et al., 2012
miR-26 Inflammation 770 NF-kB/IL-6 Ji et al., 2009
Stem-like Stem cell function 932 EpCAM Zhao et al. (unpublished)
Survival Survival 336 Current study
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FIGURE 1 | Seven independent gene signatures predict concordant
outcome groups. (A) Each of the 241 HCC patients (columns) was assigned
into high and low risk groups based on hierarchical clustering of the
prediction results of the 7 independent gene signatures, TP53 mutation
status (wild type vs. mutated), tumor size (<5 cm vs. >5 cm), TNM staging (I
vs. II/III) and BCLC staging (A vs. B/C); each tumor subclassification (rows)
based on the clustering results was found to be independently associated
with prognosis based on Cox Regression model. High risk, poor survival; low
risk, better survival. (B) The numbers represent the overlap of genes among
the 7 signatures. Color intensities represent the negative log10
hypergeometric p-values. A color intensity scale bar and the significance level
at p < 0.001 are indicated.
at the gene level may reflect a common set of phenotypic traits
where each trait is defined by a set of gene-expression events.
Thus, although signatures may be largely different from one
another, they may occupy overlapping prognostic space, indica-
tive of similar outcome (Massague, 2007). Due to the observed
tumor heterogeneity within the same prognostic subgroup shared
by various gene signatures, it is unlikely that all patients in a poor
outcome group will benefit from the same treatment. Moreover,
patient heterogeneity may not simply be reflected by a certain
gene signature, since similar gene expression patterns might also
be induced by different molecular mechanisms. For example,
not all patients with predicted stem cell features may benefit
from the same treatment because the stem cell features might
have arisen due to perturbation of different molecular pathways.
This suggests that convergent evolution of tumors may lead to
the development of similar gene expression patterns by indepen-
dent molecular mechanisms, perhaps due to adaptation to similar
environmental conditions. Thus, the multidimensional composi-
tion of cancer hallmarks in each tumor needs to be pinpointed
so that a rationally-designed treatment regimen can be
introduced.
We suggest an expansion of the prognostic space model into
what we term a biological space model, which incorporates tumor
heterogeneity (Figure 2). In this modified model, patient sub-
groups are represented as planets, which reside on orbits cor-
responding to their key signaling pathways. Although patient
subgroups may share a common prognosis, the driving signal-
ing pathway, whether singular or multiple, may have a significant
effect on the resultant composition of the tumor, and hence
its placement in the biological space. Moreover, the dynamic
nature of this model, represented by the size, shape and width
of the signaling pathway orbits, takes into account the important
role of tumor plasticity, which allows tumors to adapt to selec-
tive pressure due to treatment or tumor environmental changes
such as increased nutrient demand in the growing tumor mass.
Thus, over time the position of a patient subgroup (planet) may
change representing for example the development of resistance
to a certain drug. This revised model builds upon the premise
that although signatures share a common prognostic space, each
carries unique molecular changes, which are linked to different
sets of cancer hallmarks that collectively occupy different tumor
biological space.
www.frontiersin.org April 2014 | Volume 2 | Article 12 | 3
Roessler et al. Cancer heterogeneity and its biological space
FIGURE 2 | A model depicts the relationship between the biological
space and the prognostic space. Multiple patient subgroups exist
because of tumor heterogeneity. Analogous to planets, various patients’
subgroups reside on orbits, each of which carries key unique signaling
pathways. Representative altered signaling pathways such as MYC, TP53,
etc, are indicated. The patients’ subgroups whose orbits intersect with the
prognostic space are considered those with similar prognostic outcome.
Our progress in understanding the mechanisms of cancer
development and progression over the last three decades, has led
to the development of mechanism-based therapies to treat cancer
patients. Ideally, targeted therapeutics will be developed for each
of the 10 cancer hallmarks. However, it is currently a challenge to
identify a particular hallmark or a newly emerged molecular net-
work as a therapeutic target for a particular tumor. Recent efforts
of the Pan-Cancer initiative on the first 12 tumor types collected
and analyzed by The Cancer Genome Atlas (TCGA) have begun
to lay a framework to assemble coherent, consistent TCGA
data sets across tumor types and across platforms (The Cancer
Genome Atlas Research Network et al., 2013). Consequently,
the list of cancer-associated genes has grown rapidly with the
large sample size attained by TCGA. However, the search across
different cancer types shows that increased sample size may also
increase the number of false positive genes due to heterogeneity
in mutation frequency (Lawrence et al., 2013, 2014; The Cancer
Genome Atlas Research Network et al., 2013). A recent study
in breast cancer analyzing driver mutations and copy number
changes in cancer driver genes showed that the number of
mutated driver genes varies greatly between individual patients
(Stephens et al., 2012). Of the 40 cancer driver genes, 33 genes,
each of which is altered relatively infrequently, were responsible
for 42% of the driving genetic events. Thus, many infrequently
mutated genes collectively and substantially contribute to tumor
development, making it very challenging to select the best treat-
ment option for each cancer patient. In addition, it is challenging
to identify specific hallmarks because one particular genetic
change does not always reflect cancer vulnerability. For instance,
a gene mutation may not imply that tumor survival depends
on this gene, although the mutation may be important in the
early genesis of this tumor. Furthermore, different combinations
of affected genes may give rise to a different dependency for a
particular tumor subgroup. One strategy to search for cancer
vulnerabilities is to use in vivo screens such as transposon
mutagenesis or RNAi (Zender et al., 2008; Bard-Chapeau et al.,
2013). The limitation is that the findings are based on animal
models, which may or may not be relevant to human tumor sub-
types. Conceivably, integrative analysis incorporating biological
and clinical factors will be necessary to tease apart differences in
tumors, rooted in heterogeneity, to identify critical biomarkers for
cancer diagnosis and clinically relevant therapeutic targets that
represent convergent cancer driving molecular hubs. Therefore,
the TCGA Pan-Cancer initiative seeks to incorporate multiple
omics data with genomic sequencing (The Cancer Genome
Atlas Research Network et al., 2013). Such an approach requires
the development of new bioinformatics tools. For example, we
have developed an approach to integrate somatic copy number
alterations and transcriptome to identify novel tumor suppressor
genes in HCC (Roessler et al., 2012). We also integrated mRNA
and microRNA expression profiles and identified key signaling
pathway in stem-cell like intrahepatic cholangiocarcinoma (Oishi
et al., 2012). Integration of metabolomic and mRNA expression
profiles resulted in the identification of a key lipogenic pathway
and the druggable target SCD in HCC (Budhu et al., 2013).
Most recently, we developed an unsupervised tumor subgroup
discovery tool, namely iSubgraph, which is based on graph
mining and mixture models, to integrate various omics-based
data (Ozdemir et al., 2013). It is anticipated that the integration
of multiple levels of data such as genomic mutations, somatic
copy number aberration, gene expression, proteomics, and
metabolomics, may help us grasp the tumor biological space
occupied by each individual. The dynamic nature of the biolog-
ical space of each tumor takes into account the important role of
tumor plasticity which is the main reason for the development of
drug resistance. Therefore, it will be crucial not only to assess the
main cancer driving event, but also to predict which resistance
mechanisms a tumor might develop in order to select suitable
drug combinations, which can lead to improved therapeutic
intervention and outcome. We believe that in vivo mutagenesis
screens to identify cancer drivers in animal tumor models would
complement efforts from integrative omics based profiling of
patient biospecimens to facilitate the identification of molecular
tumor subgroups and cancer vulnerable molecular targets.
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